1. Home
  2. BNR vs RFL Comparison

BNR vs RFL Comparison

Compare BNR & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

N/A

Current Price

$9.40

Market Cap

94.4M

Sector

Health Care

ML Signal

N/A

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$2.20

Market Cap

92.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
RFL
Founded
2014
2017
Country
China
United States
Employees
N/A
N/A
Industry
Medical Specialities
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
94.4M
92.6M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
BNR
RFL
Price
$9.40
$2.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.1K
236.8K
Earning Date
06-05-2026
06-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.28
EPS
N/A
N/A
Revenue
N/A
$917,000.00
Revenue This Year
$111.65
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$5.31
$1.12
52 Week High
$41.72
$3.96

Technical Indicators

Market Signals
Indicator
BNR
RFL
Relative Strength Index (RSI) 46.02 49.67
Support Level $8.34 $1.21
Resistance Level $10.00 $3.96
Average True Range (ATR) 0.78 0.25
MACD -0.01 -0.06
Stochastic Oscillator 17.10 53.12

Price Performance

Historical Comparison
BNR
RFL

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: